---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-057525"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T21:56:15.291408+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio CEO letter details Phase II/III AD data; will narrow enrollment to early-stage patients for next trial

## Summary
- Phase II/III study in MMSE 21-24 patients: buntanetap showed ADAS-Cog11 improvement of -2.36 vs placebo at 3 months.
- In moderate AD (MMSE 14-20), improvement was -0.65 vs placebo +1.79, indicating high placebo effect.
- Next Phase III will prescreen for plasma AD biomarkers and enroll only early/mild AD (MMSE 21-28).
- CEO states FDA will accept buntanetap for symptomatic relief and allow continuation for disease-modification study.

## SEC filing metadata
- accession: 0001104659-24-057525
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924057525/0001104659-24-057525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924057525/tm2413238d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-057525
- JSON: https://secwatch.observer/filing/0001104659-24-057525.json
- Plain text: https://secwatch.observer/filing/0001104659-24-057525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.